Literature DB >> 24905873

Recent advances in nanoparticle-mediated siRNA delivery.

John-Michael Williford1, Juan Wu, Yong Ren, Maani M Archang, Kam W Leong, Hai-Quan Mao.   

Abstract

Inhibiting specific gene expression by short interfering RNA (siRNA) offers a new therapeutic strategy to tackle many diseases, including cancer, metabolic disorders, and viral infections, at the molecular level. The macromolecular and polar nature of siRNA hinders its cellular access to exert its effect. Nanoparticulate delivery systems can promote efficient intracellular delivery. Despite showing promise in many preclinical studies and potential in some clinical trials, siRNA has poor delivery efficiency, which continues to demand innovations, from carrier design to formulation, in order to overcome transport barriers. Previous findings for optimal plasmid DNA delivery cannot be generalized to siRNA delivery owing to significant discrepancy in size and subtle differences in chain flexibility between the two types of nucleic acids. In this review, we highlight the recent advances in improving the stability of siRNA nanoparticles, understanding their intracellular trafficking and release mechanisms, and applying judiciously the promising formulations to disease models.

Entities:  

Keywords:  gene therapy; intracellular trafficking; nanoparticle; siRNA delivery; stability

Mesh:

Substances:

Year:  2014        PMID: 24905873     DOI: 10.1146/annurev-bioeng-071813-105119

Source DB:  PubMed          Journal:  Annu Rev Biomed Eng        ISSN: 1523-9829            Impact factor:   9.590


  38 in total

Review 1.  Micro and nanoparticle drug delivery systems for preventing allotransplant rejection.

Authors:  James D Fisher; Abhinav P Acharya; Steven R Little
Journal:  Clin Immunol       Date:  2015-05-01       Impact factor: 3.969

2.  Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems.

Authors:  Anish Babu; Anupama Munshi; Rajagopal Ramesh
Journal:  Drug Dev Ind Pharm       Date:  2017-05-19       Impact factor: 3.225

Review 3.  Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran.

Authors:  Simoneide S Titze-de-Almeida; Pedro Renato de Paula Brandão; Ingrid Faber; Ricardo Titze-de-Almeida
Journal:  Mol Diagn Ther       Date:  2020-02       Impact factor: 4.074

4.  Efficient tuning of siRNA dose response by combining mixed polymer nanocarriers with simple kinetic modeling.

Authors:  Chad T Greco; Victoria G Muir; Thomas H Epps; Millicent O Sullivan
Journal:  Acta Biomater       Date:  2017-01-04       Impact factor: 8.947

Review 5.  Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy.

Authors:  Anish Babu; Ranganayaki Muralidharan; Narsireddy Amreddy; Meghna Mehta; Anupama Munshi; Rajagopal Ramesh
Journal:  IEEE Trans Nanobioscience       Date:  2016-12       Impact factor: 2.935

6.  The Effects of Biological Fluids on Colloidal Stability and siRNA Delivery of a pH-Responsive Micellar Nanoparticle Delivery System.

Authors:  Dominic W Malcolm; Jomy J Varghese; Janet E Sorrells; Catherine E Ovitt; Danielle S W Benoit
Journal:  ACS Nano       Date:  2017-12-15       Impact factor: 15.881

7.  Shape Control in Engineering of Polymeric Nanoparticles for Therapeutic Delivery.

Authors:  John-Michael Williford; Jose Luis Santos; Rishab Shyam; Hai-Quan Mao
Journal:  Biomater Sci       Date:  2015-07       Impact factor: 6.843

8.  Delivery of Small Interfering RNA to Inhibit Vascular Endothelial Growth Factor in Zebrafish Using Natural Brain Endothelia Cell-Secreted Exosome Nanovesicles for the Treatment of Brain Cancer.

Authors:  Tianzhi Yang; Brittany Fogarty; Bret LaForge; Salma Aziz; Thuy Pham; Leanne Lai; Shuhua Bai
Journal:  AAPS J       Date:  2016-11-23       Impact factor: 4.009

Review 9.  Protocells: Modular Mesoporous Silica Nanoparticle-Supported Lipid Bilayers for Drug Delivery.

Authors:  Kimberly S Butler; Paul N Durfee; Christophe Theron; Carlee E Ashley; Eric C Carnes; C Jeffrey Brinker
Journal:  Small       Date:  2016-01-18       Impact factor: 13.281

Review 10.  Ligand-targeted theranostic nanomedicines against cancer.

Authors:  Virginia J Yao; Sara D'Angelo; Kimberly S Butler; Christophe Theron; Tracey L Smith; Serena Marchiò; Juri G Gelovani; Richard L Sidman; Andrey S Dobroff; C Jeffrey Brinker; Andrew R M Bradbury; Wadih Arap; Renata Pasqualini
Journal:  J Control Release       Date:  2016-01-06       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.